Currently we estimate that in Europe and North America 900 active clinical trials comprising and recruiting up to 60’000 patients could benefit from our technology. We observe that non-commercial entities perform 2/3 of the studies mainly in phase I & II. Commercial entities then focus on the 1/3 remaining with mostly phases II & III.
There is nowadays in Europe, North America and European neighbouring countries more than 4.5 million infected people with sicknesses that could be cured by ex vivo gene therapies as soon as they become more common. The treatment potential of upcoming gene therapies, would allow to heal most of the currently infected people.